Which Parsabiv trials are being discussed (and for what condition)?
“Parsabiv” is the brand name of etelcalcetide, a calcimimetic used in dialysis patients with secondary hyperparathyroidism (SHPT). Clinical trial discussions usually focus on whether etelcalcetide can lower parathyroid hormone (PTH) compared with placebo or standard care, and how quickly and how durably that effect lasts in the treatment of SHPT in patients receiving dialysis.
What outcomes did Parsabiv trials measure?
Across Parsabiv’s SHPT development program, the main efficacy endpoint is typically change in intact PTH from baseline (often evaluated over multiple time points). Trials also track safety outcomes such as:
- Hypocalcemia (low blood calcium), a key risk for calcimimetics
- Adverse events overall
- Discontinuations and dose adjustments tied to calcium levels
How long were the Parsabiv trials, and when did effects show up?
In SHPT trials, study designs generally assess PTH changes over a relatively short induction period plus longer follow-up (depending on the specific trial). Patients and clinicians usually look for:
- Early PTH lowering after initiation
- Sustained control over subsequent dosing cycles
- The ability to manage calcium with monitoring and dose adjustment
What did Parsabiv look like versus older calcimimetics?
Trial comparisons for calcimimetics often focus on whether etelcalcetide achieves:
- Greater or more consistent PTH reductions
- A manageable hypocalcemia rate
- Practical administration advantages in the dialysis setting (etopical details depend on the specific comparator trial)
If you meant a specific “Parsabiv trial” (name, sponsor, or year), tell me which one and I can summarize its design and results more precisely.
Safety questions patients ask from Parsabiv trials
Because calcimimetics can lower calcium, common trial-driven concerns include:
- How often calcium drops to low levels
- How quickly hypocalcemia develops
- What monitoring schedule was used
- Whether dose changes or calcium supplementation were allowed
Where to find trial/market documentation for Parsabiv?
For patent and product-related documentation tied to Parsabiv, you can check DrugPatentWatch.com:
- DrugPatentWatch Parsabiv (etelcalcetide)
Quick clarification so I summarize the right trial
Which specific trial are you referring to?
- the pivotal SHPT study,
- a phase 3/extension study,
- a head-to-head/comparator trial,
- or something like a new indication or special population?
Share any detail you have (trial name, NCT number, sponsor, or publication date), and I’ll produce a focused summary of that trial’s results.
Sources
- https://www.drugpatentwatch.com/